Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation

被引：0
|
作者：
De Summa, S. [1 ]
Pinto, R. [1 ]
Strippoli, S. [1 ]
Natalicchio, I. [2 ]
Azzariti, A. [1 ]
Cramarossa, A. [1 ]
Signorile, M. [1 ]
Albano, A. [1 ]
Lorusso, V. [1 ]
Guida, G. [3 ]
Guida, M. [1 ]
Tommasi, S. [1 ]
机构：
[1] IRCCS Ist Tumori Giovanni Paolo II Bari, Bari, Italy
[2] Az Osped Univ Osp Riuniti Foggia, Bari, Italy
[3] Univ Bari, Scuola Med, Bari, Italy
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B03
引用
收藏
页码：26 / 27
页数：2
相关论文
共 50 条
  • [41] Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
    Linh T. Nguyen
    Samuel D. Saibil
    Valentin Sotov
    Michael X. Le
    Leila Khoja
    Danny Ghazarian
    Luisa Bonilla
    Habeeb Majeed
    David Hogg
    Anthony M. Joshua
    Michael Crump
    Norman Franke
    Anna Spreafico
    Aaron Hansen
    Ayman Al-Habeeb
    Wey Leong
    Alexandra Easson
    Michael Reedijk
    David P. Goldstein
    David McCready
    Kazuhiro Yasufuku
    Thomas Waddell
    Marcelo Cypel
    Andrew Pierre
    Bianzheng Zhang
    Sarah Boross-Harmer
    Jane Cipollone
    Megan Nelles
    Elizabeth Scheid
    Michael Fyrsta
    Charlotte S. Lo
    Jessica Nie
    Jennifer Y. Yam
    Pei Hua Yen
    Diana Gray
    Vinicius Motta
    Alisha R. Elford
    Stephanie DeLuca
    Lisa Wang
    Stephanie Effendi
    Ragitha Ellenchery
    Naoto Hirano
    Pamela S. Ohashi
    Marcus O. Butler
    [J]. Cancer Immunology, Immunotherapy, 2019, 68 : 773 - 785
  • [42] Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
    Nguyen, Linh T.
    Saibil, Samuel D.
    Sotov, Valentin
    Le, Michael X.
    Khoja, Leila
    Ghazarian, Danny
    Bonilla, Luisa
    Majeed, Habeeb
    Hogg, David
    Joshua, Anthony M.
    Crump, Michael
    Franke, Norman
    Spreafico, Anna
    Hansen, Aaron
    Al-Habeeb, Ayman
    Leong, Wey
    Easson, Alexandra
    Reedijk, Michael
    Goldstein, David P.
    McCready, David
    Yasufuku, Kazuhiro
    Waddell, Thomas
    Cypel, Marcelo
    Pierre, Andrew
    Zhang, Bianzheng
    Boross-Harmer, Sarah
    Cipollone, Jane
    Nelles, Megan
    Scheid, Elizabeth
    Fyrsta, Michael
    Lo, Charlotte S.
    Nie, Jessica
    Yam, Jennifer Y.
    Yen, Pei Hua
    Gray, Diana
    Motta, Vinicius
    Elford, Alisha R.
    DeLuca, Stephanie
    Wang, Lisa
    Effendi, Stephanie
    Ellenchery, Ragitha
    Hirano, Naoto
    Ohashi, Pamela S.
    Butler, Marcus O.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (05) : 773 - 785
  • [43] Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort
    Movva, Sujana
    Druta, Mihaela
    Davis, Lara E.
    Monga, Varun
    Milhem, Mohammed M.
    Bailey, Howard Harry
    Chugh, Rashmi
    Bruns, Ingmar
    Allgood, Victoria E.
    Chawla, Sant P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): A phase II clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination
    Fontana, A.
    Bocci, G.
    Galli, L.
    Fontana, E.
    Antonuzzo, A.
    Galli, C.
    Loupakis, F.
    Allegrini, G.
    Di Marsico, R.
    Landi, L.
    LoDico, M.
    Mazzoni, E.
    Safina, V
    Barletta, M.
    Andreuccetti, M.
    Barsanti, G.
    Fioravanti, A.
    Orlandi, P.
    Del Tacca, M.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI79 - XI79
  • [45] Low-dose metronomic cyclophosphamide plus celecoxib and dexamethasone in advanced hormone refractory prostate cancer (HRPC): A phase ii clinical trial with evaluation of clinical, biologic and pharmacodynamic effects of the combination
    Fontana, Andrea
    Bocci, Guido
    Fontana, Eloise
    Galli, Costanza
    Loupakis, Fotios
    Landi, Lorenza
    Lo Dico, Monica
    Mazzoni, Enrica
    Barsanti, Gemma
    Falcone, Alfredo
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 150 - 150
  • [46] Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
    Groenewegen, G
    Bloem, A
    de Gast, GC
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (11-12) : 630 - 636
  • [47] Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
    Gerard Groenewegen
    Andries Bloem
    Gijsbert C. de Gast
    [J]. Cancer Immunology, Immunotherapy, 2002, 51 : 630 - 636
  • [48] Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+and CD8+T cells in combination with low-dose interferon-alpha
    Verdegaal, Els M. E.
    Visser, Marten
    Ramwadhdoebe, Tamara H.
    van der Minne, Caroline E.
    van Steijn, Jeanne A. Q. M. J.
    Kapiteijn, Ellen
    Haanen, John B. A. G.
    van der Burg, Sjoerd H.
    Nortier, Johan W. R.
    Osanto, Susanne
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) : 953 - 963
  • [49] Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil
    Kuypers, DRJ
    Vanrenterghem, Y
    Squifflet, JP
    Mourad, M
    Abramowicz, D
    Oellerich, M
    Armstrong, V
    Shipkova, M
    Daems, J
    [J]. THERAPEUTIC DRUG MONITORING, 2003, 25 (05) : 609 - 622
  • [50] Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha
    Els M. E. Verdegaal
    Marten Visser
    Tamara H. Ramwadhdoebé
    Caroline E. van der Minne
    Jeanne A. Q. M. J. van Steijn
    Ellen Kapiteijn
    John B. A. G. Haanen
    Sjoerd H. van der Burg
    Johan W. R. Nortier
    Susanne Osanto
    [J]. Cancer Immunology, Immunotherapy, 2011, 60 : 953 - 963
12345